Arecor Therapeutics (AREC) Investor presentation summary

Strategic focus and market opportunity

• Developing advanced therapeutics for diabetes, obesity, and cardiometabolic diseases, targeting significant unmet needs and multi-billion dollar markets.

• AT278, an ultra-concentrated, ultra-rapid insulin, aims to transform automated insulin delivery (AID) systems and expand access for high insulin users.

• Oral peptide delivery platform in development, initially targeting GLP-1 drugs for obesity, with preclinical data expected in 2026.

• Multiple programs are partnered with leading pharma companies, enhancing pipeline value and de-risking development.

• Cash runway extends into 1H 2027, supported by royalty finance agreements and revenue from partnerships.

AT278 clinical development and results

• AT278 is the first insulin enabling pump use for high insulin users, supporting longer wear and smaller AID systems.

• Phase 1 studies in T1D and T2D showed AT278 met all primary and secondary endpoints, with superior PK/PD profiles versus NovoRapid and Humulin R U500.

• Demonstrated faster onset, higher early exposure, and greater glucose-lowering action compared to standard insulins.

• No safety signals detected in clinical trials.

• Phase 2 clinical study in combination with Sequel AID system planned for 2H 2026.

Market potential and adoption drivers

• US AID market is underpenetrated, with a $20B opportunity and significant growth projected globally (CAGR +15%).

• AT278 addresses the needs of 1M+ US patients unable to achieve 3-day wear with current pumps, representing a $3B+ initial TAM.

• Concentrated insulin is essential for longer wear in pumps, especially for T2Ds and high-dose T1Ds.

• Partnership with Sequel Med Tech aims to co-develop next-generation, longer-wear AID systems.

• Strategic intent to expand co-development and commercialization of AT278 in innovative AID systems.